Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?

by Zacks Equity Research

During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.

Cronos (CRON) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when the company reports Q1 results.

What's in the Cards for Corbus (CRBP) This Earnings Season?

by Zacks Equity Research

Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.

Mylan (MYL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.

What's in Store for Sorrento (SRNE) This Earnings Season?

by Zacks Equity Research

Sorrento (SRNE) may provide update on progress of ZTlido on the first quarter earnings call.

Regeneron (REGN) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter results.

PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.

What's in Store for BioDelivery (BDSI) This Earnings Season?

by Zacks Equity Research

Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

What's in the Cards for AEterna (AEZS) This Earnings Season?

by Zacks Equity Research

AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.

Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.

Horizon Pharma (HZNP) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Horizon Pharma (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Novavax (NVAX) This Earnings Season?

by Zacks Equity Research

Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.

What's in the Cards for Sarepta (SRPT) This Earnings Season?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.

Why the Earnings Surprise Streak Could Continue for Horizon Pharma (HZNP)

by Zacks Equity Research

Horizon Pharma (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Is Horizon Pharma (HZNP) Down 9.9% Since Last Earnings Report?

by Zacks Equity Research

Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Company News For Mar 1, 2019

by Zacks Equity Research

Companies In The News Are: BKNG, HPQ, LB, HZNP

Sanghamitra Saha headshot

Why These Pharma ETFs Rallied on Thursday

by Sanghamitra Saha

A few pharma ETFs hit a one-month high on Feb 28. Why?

Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat

by Zacks Equity Research

Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.

Horizon Pharma (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Horizon Pharma (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Horizon Pharma (HZNP) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Horizon Pharma (HZNP) stock based on the movements in the options market lately.

Horizon Pharma (HZNP) Up 28% on Business Expansion Strategy

by Zacks Equity Research

Horizon Pharma's (HZNP) share price increases about 28% based on its business expansion plan and acquisitions.

Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group

by Zacks Equity Research

Horizon Pharma's Ravicti Oral Liquid gets FDA approval to expand the age range to include infants younger than two months, living with a urea cycle disorder.

Horizon Pharma (HZNP) Down 9.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise

by Zacks Equity Research

Shares of Horizon Pharma (HZNP) rise almost 16%, owing to record quarterly sales during the third quarter of 2018.